UnknownNot Applicable

Calprotectin for Rapid Diagnostic Infection Spontaneous of Ascites

France218 participantsStarted 2015-02

Plain-language summary

The prognosis of spontaneous bacterial peritonitis (ISLA) remains a serious complication of cirrhosis. Rapid diagnosis of ISLA is a key issue for improving the prognosis. The determination of calprotectin in ascites, used for the diagnosis of infection of ascitic liquid, could allow the diagnosis in a very short time (about 30 minutes). To date, the determination of calprotectin in ascites was not evaluated properly. The investigators would thus evaluate the interest of the determination of calprotectin in ascites for the rapid diagnosis of ISLA in cirrhotic patients, like you, hospitalized for decompensation of their disease. The main purpose of this pilot study will determine the optimal threshold calprotectin in ascites for diagnosis of ISLA.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Man or woman over 18 years * Presence of ascites due to cirrhosis * Hospitalization for a complication of cirrhosis (first or recurrent ascites ascites decompensation requiring prolonged hospitalization, gastrointestinal bleeding, encephalopathy, etc ...). Exclusion Criteria: * Patients with ascites admitted to the hospital for a suspected infection and receiving an antibiotic for more than 12 hours (patients with antibiotic prophylaxis with norfloxacin with a clinical suspicion of ISLA will be included in the study (there may be in this case ISLA germs resistant to quinolones). * Outpatient hospital to perform paracentesis evacuative * Chylous ascites, * Hemorrhagic Ascites * Ascites not related to portal hypertension (peritoneal carcinomatosis, pancreatic ascites, tuberculosis, etc ...) * comatose patients under guardianship or does not have all their mental faculties

What they're measuring

Measurement of the calprotectin level in ascitic fluid with Quantum Blue® Reader

Timeframe: 18 months

Trial details

NCT IDNCT02857101

SponsorCentre Hospitalier Universitaire de Besancon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-02

Contact for this trial

Delphine WEIL-VERHOVEN, MD

dweil@chu-besancon.fr